Mobile website
Archive > Volume 20 Issue 6 > 2013,20(6):700-705. DOI:10.3872/j.issn.1007-385X.2013.06.012 Prev Next
Basic Research
Effect of recombinant super-compound interferon on proliferation, apoptosis and resistance to epirubicin of human breast cancer cell MCF-7/ADR
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To observe the effect of recombinant super-compound interferon (rSIFN-co) on the proliferation, apoptosis and resistance to epirubicin of human breast cancer MCF-7/ADR cells (a multi-drug resistance \[MDR\] strain), and to investigate the possible mechanism. Methods: MCF-7/ADR cells were treated with rSIFN-co, epirubicin alone or combaination, and the MCF-7 cells were used as control. MTT assay and flow cytometry were performed to detect the effect of rSIFN-co on the proliferation and apoptosis of MCF-7/ADR cells, respectively. Immunohistochemical staining was used to detect the influence of rSIFN-co on the P-gp expression level in MCF-7/ADR cells. Results: After treated by different drugs for 24 h, the growth inhibition rate of MCF-7/ADR cells treated by 0.078 μg/ml rsIFN-co or 0.02 μg/ml rsIFN-co combined with 15.00 μg/ml epirubicin was significantly higher than that treated by 100.00 μg/ml epirubicin (\[29.7±1.4\]%, \[23.0±2.1\]% vs \[17.1±1.5\]%; all P<0.01). The inhibition effect of each drug had a dose and time dependence. Synergistic effect of rSIFN-co with epirubicin was also observed after being treated for 72 h. Epirubicin showed no significant effect on MCF-7/ADR cells′ apoptosis after treated for 24 h (P>0.05); however, use of rSIFN-co alone or combined with epirubicin significantly enhanced the apoptosis rate than did epirubicin alone after 24 h (\[3537±1.40\]%, \[61.37±1.76\]% vs \[9.80±1.66\]%; all P<0.01), and the effects on cell apoptosis had a time dependence (P<0.01); and the synergistic effect of rSIFN-co with epirubicin was also observed. Compared with the control group (3.94±0.0088), the P-gp expression was increased in the epirubicin group (4.17±0.0252, P<0.01), but decreased in rSIFN-co group (2.59±0.0260, P<0.01) and the combined group (2.62±0.0100, P<0.01).There was no significant difference between the combined group and rsIFN-co group in P-gp expression (P=0.948). Conclusion: rSIFN-co can inhibit cell growth, induce cell apoptosis of human breast cancer MCF-7/ADR cells, and reverse the multi-drug resistance by decreasing the expression of P-gp.
Keywords:
Project Supported:
Project supported by the Science and Technology Project of Sichuan Province（No. 0040205301164）
Clc Number:
